Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes.
Paulus KirchhofTobias ToennisAndreas GoetteA John CammHans Christoph DienerNina BecherEmanuele BertagliaCarina Blomstrom LundqvistMartin BorlichAxel BrandesNuno CabanelasMelanie CalvertGregory ChlouverakisGheorghe-Andrei DanJoris R de GrootWolfgang DichtlBorys KravchukAndrzej LubińskiEloi MarijonBéla MerkelyLluís MontAnn-Kathrin OzgaKim RajappanAndrea SarkozyDaniel ScherrRafał SznajderVasil VelchevDan WichterleSusanne SehnerEmmanuel SimantirakisGregory Y H LipPanos VardasUlrich SchottenAntonia Zapfnull nullPublished in: The New England journal of medicine (2023)
Among patients with AHREs detected by implantable devices, anticoagulation with edoxaban did not significantly reduce the incidence of a composite of cardiovascular death, stroke, or systemic embolism as compared with placebo, but it led to a higher incidence of a composite of death or major bleeding. The incidence of stroke was low in both groups. (Funded by the German Center for Cardiovascular Research and others; NOAH-AFNET 6 ClinicalTrials.gov number, NCT02618577; ISRCTN number, ISRCTN17309850.).